Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR441255 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| SAR441255 | EXPERIMENTAL | Single dose, subcutaneous, escalating dose |
| Placebo | PLACEBO_COMPARATOR | Single dose, subcutaneous, matched volume |
| Name | Type | Description |
|---|---|---|
| SAR441255 | DRUG | Pharmaceutical form:solution for injection Route of administration: subcutaneous |
| placebo | DRUG | Pharmaceutical form:solution for injection Route of administration: subcutaneous |
Inclusion criteria : * Male and female subjects, between 18 and 55 years of age, inclusive * Body Mass Index ≥20 and ≤30 kg/m2 * Body weight between 65 and 90 kg, inclusive * No concomitant medication * Fasting Plasma Glucose \<126 mg/dL * Hemoglobin A1c \<6.5% * Triglycerides \<300 mg/dL * Low-den...
SAR441255 is an investigational small molecule being developed for the treatment of overweight. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The molecular target of SAR441255 has not been disclosed. It is a small molecule being studied for its effects on overweight, but its specific mechanism of action is not publicly available.
SAR441255 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical trials.
SAR441255 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not been approved for any use.
SAR441255 has been studied in one completed Phase 1 trial, NCT04521738, which assessed the safety and tolerability of a single subcutaneous dose in lean to overweight subjects. The trial enrolled 48 participants in the United States.
No alternative names for SAR441255 have been reported. It is identified solely by its code name SAR441255 in clinical trial records.